Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.55 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.48 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23345343 | 1.00 | KMT2A (0.58) | KMT2APOLBSMN1; SMN2CYP1A2GSK3B | |
| SCHEMBL1769120 | 1.00 | KMT2A (0.58) | KMT2APOLBSMN1; SMN2CYP1A2GSK3B | |
| SCHEMBL11928783 | 0.87 | CYP1A2 (0.53) | KMT2APOLBSMN1; SMN2CYP1A2GSK3B | |
| SCHEMBL6117540 | 0.87 | CYP1A2 (0.53) | KMT2APOLBSMN1; SMN2CYP1A2GSK3B | |
| SCHEMBL6117537 | 0.87 | CYP1A2 (0.53) | KMT2APOLBSMN1; SMN2CYP1A2GSK3B | |
| SCHEMBL23345327 | 0.86 | HTT (0.51) | KMT2APOLBSMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL1769027 | 0.85 | CYP1A2 (0.57) | KMT2APOLBSMN1; SMN2CYP1A2GSK3B | |
| SCHEMBL23326817 | 0.85 | CYP1A2 (0.57) | KMT2APOLBSMN1; SMN2CYP1A2GSK3B | |
| SCHEMBL28360448 | 0.85 | LMNA (0.45) | KMT2APOLBSMN1; SMN2CYP1A2MAPT | |
| SCHEMBL1769024 | 0.85 | CYP1A2 (0.57) | KMT2APOLBSMN1; SMN2CYP1A2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4582427-A1 | USP1 INHIBITOR | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) | 2025-07-09 | — | — | EP | disclosed |
| CN-110577485-B | Norcamphor derived [2, 1] -bridged ring ketene compounds and synthesis method and application thereof | 武汉大学 | 2022-11-04 | — | — | CN | disclosed |
| CN-115108938-A | Chiral alpha-substituted deuterated amino acid compound and preparation method thereof | 武汉大学 | 2022-09-27 | — | — | CN | disclosed |
| CN-114940661-A | Norcamphor derived [2,2,1] -bridged ketene compounds and synthesis method and application thereof | 武汉大学 | 2022-08-26 | — | — | CN | disclosed |
| CN-114349585-A | Catalytic asymmetric synthesis method and application of chiral alpha-deuterated pyrrolidine compound | 武汉大学 | 2022-04-15 | — | — | CN | disclosed |
| CN-110577485-A | Norcamphor derived [2,2,1] -bridged ketene compounds and synthesis method and application thereof | 武汉大学 | 2019-12-17 | — | — | CN | disclosed |
| CN-106478645-A | A kind of fragrant cyclosubstituted spiro indole diketopiperazine compound and its synthetic method | 陕西科技大学 | 2017-03-08 | — | — | CN | disclosed |
| US-9321769-B2 | Heterocyclic acrylamides and their use as pharmaceuticals | FAB PHARMA S.A.S. (FR) | 2016-04-26 | — | — | US | disclosed |
| US-20150232466-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | FAB PHARMA S.A.S. (FR) | 2015-08-20 | — | — | US | disclosed |
| US-9051321-B2 | Heterocyclic acrylamides and their use as pharmaceuticals | FAB PHARMA S.A.S. (FR) | 2015-06-09 | — | — | US | disclosed |
| EP-2501693-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | FAB Pharma SAS (FR) | 2012-09-26 | — | — | EP | disclosed |
| US-8034810-B2 | Matrix metalloproteinase inhibitors; antiinflammatory agengs; rheumatoid arthritis, osteoarthritis; antitumor, anticarcinogenic, and antimetastasis agents; respiratory system disorders, chronic obstructive pulmonary disease, deblocking, deprotecting | NOVARTIS AG (CH) | 2011-10-11 | — | — | US | disclosed |
| WO-2011061214-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | FAB PHARMA SAS (FR) | 2011-05-26 | — | — | WO | disclosed |
| EP-1202961-B1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2010-01-20 | — | — | EP | disclosed |
| EP-2085379-A1 | Arylsulfonamido-substituted hydroxamic acid derivatives | Novartis AG (CH) | 2009-08-05 | — | — | EP | disclosed |
| US-20080275127-A1 | Arylsulfonamido-substituted hydroxamic acid derivatives | BREITENSTEIN WERNER | 2008-11-06 | — | — | US | disclosed |
| US-7138432-B1 | Arylsulfonamido-substituted hydroxamic acid derivatives | NOVARTIS AG (CH) | 2006-11-21 | — | — | US | disclosed |
| EP-1202961-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | Novartis AG (CH) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001010827-A1 | ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES | NOVARTIS AG (CH) | 2001-02-15 | — | — | WO | disclosed |
| US-5569661-A | Process for the production of b-carbolines | SCHERING AKTIENGESELLSCHAFT (DE) | 1996-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232466-A1 | NOVEL HETEROCYCLIC ACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | ACR, AADAC, AAAS | KMT2A 4479/4885POLB 2880/4885SMN1; SMN2 4165/4885 |
| US-20080275127-A1 | Arylsulfonamido-substituted hydroxamic acid derivatives | MMP13, MMP2, MMP1 | KMT2A 2171/4885POLB 1365/4885SMN1; SMN2 4344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.